Commercial-Scale Cell Therapy CDMOs
36
CDMOs tracked
36
Fully scored
17
With FDA records
51
FDA inspections
136
EMA/MHRA GMP certs
6
Warning letters
Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.
The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 25 NAI (no action), 25 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (41), Germany (29), UNITED KINGDOM (22), Denmark (18), Ireland (16).
Last updated 2026-06-24. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 7 insp · 11 GMP | Limited | 0 programs |
| 2 |
BMS
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
|
90.8 | 97.0 | 5 insp · 2 GMP | — | 576 programs |
| 3 |
COH
City of Hope (T Cell Manufacturing)
Duarte, CA
|
83.8 | 96.8 | 3 insp · 0 GMP | — | 207 programs |
| 4 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 5 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.5 | 100.0 | 1 insp · 6 GMP | Limited | 0 programs |
| 6 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 2 insp · 2 GMP | — | 22 programs |
| 7 |
SC
SCTbio
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 8 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 4 insp · 0 GMP | — | 0 programs |
| 9 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 10 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 1 insp · 23 GMP | Available | 2 programs |
| 11 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 3 insp · 18 GMP | — | 100 programs |
| 12 |
CF
CELLforCURE (SEQENS)
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 13 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| 14 |
SG
Syngene International
Bangalore, India
|
79.7 | 95.9 | 2 insp · 0 GMP | — | 0 programs |
| 15 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 16 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 17 |
BY
Bayer (Cell Therapy Mfg)
Berkeley, CA
|
79.2 | 86.9 | 8 insp · 16 GMP | — | 125 programs |
| 18 |
CS
Cedars-Sinai Biomanufacturing
Los Angeles, CA
|
78.9 | 100.0 | 1 insp · 0 GMP | — | 31 programs |
| 19 |
XP
eXmoor Pharma
Bristol, UK
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 20 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 21 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 22 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 23 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 24 |
CC
CCRM
Toronto, ON
|
78.1 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 25 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 26 |
GP
Green Phoenix Labs
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 27 |
BC
Biocon Biologics
Bangalore, India
|
77.1 | 96.1 | 4 insp · 1 GMP | — | 0 programs |
| 28 |
SY
Symbiosis Pharmaceutical Services
Stirling, UK
|
76.8 | 100.0 | 1 insp · 9 GMP | — | 0 programs |
| 29 |
IP
Intas Pharmaceuticals
Ahmedabad, IN
|
76.8 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 30 |
CY
Cell-Easy
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 31 |
CN
Cellin Technologies
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 32 |
HH
HiTech Health
London, UK
|
76.8 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 33 |
FH
Fred Hutch Cell Therapy Lab
Seattle, WA
|
76.4 | — | — | — | 450 programs |
| 34 |
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
|
74.6 | 100.0 | 0 insp · 2 GMP | — | 8 programs |
| 35 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |
| 36 |
IO
Iovance Biotherapeutics (Mfg)
Philadelphia, PA
|
70.8 | — | — | — | 29 programs |
What to evaluate in a Cell Therapy CDMO
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Cell Therapy CDMOs — Frequently Asked Questions
Who are the top Cell Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include Charles River Laboratories, Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 17 Cell Therapy CDMOs with FDA inspection records and 136 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Related modalities
Other Modalities